Pharma major Cipla will release its Q4 FY25 earnings on May 13, 2025. The Board may also consider a final dividend for FY25.

With Trump's tariffs looming, is this really the appropriate time to load up on pharma stocks? And where does Cipla stand in ...

Cipla is currently headquartered in Mumbai and has extended its presence to more than 80 countries. Cipla offers an array of more than 1500 therapeutic products that echo its guiding purpose and ...

Pharma Stocks; The Indian pharma market experienced a robust growth of 9.3% year-on-year in March 2025, with key players like ...

Cipla said USFDA has approved the ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial ('Protein-bound Paclitaxel') on Apr 10 ...

Nifty FMCG index climbed as much as 1.7 percent, with key constituents such as Hindustan Unilever, ITC, Varun Beverages and ...

The American Lung Association in New York is proud to welcome Cipla back as the lead sponsor of the 2025 LUNG FORCE Walk New York City. As this year’s Breathe Free Sponsor, Cipla continues its ...

After detailed deliberation, the committee accepted the phase II clinical trial results and agreed to the firm’s proposal to ...

New Delhi: The pharmaceutical major Cipla has got the go-ahead from the Subject Expert Committee (SEC) functional under the ...

The pharma sector is likely to maintain steady earnings. Most brokerages flag US business recovery as the key swing factor ...

Vishal Manchanda, Pharma Analyst at Systematix Group, advised avoiding companies with high dependence on the US market—such ...